{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:44:57Z","timestamp":1787161497265,"version":"build-2736575974"},"reference-count":37,"publisher":"Informa UK Limited","issue":"4","license":[{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2022,3,21]]},"DOI":"10.1080\/10428194.2021.2002321","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T08:37:35Z","timestamp":1644568655000},"page":"928-938","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":27,"title":["Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy\n                    <sup>*<\/sup>"],"prefix":"10.1080","volume":"63","author":[{"given":"Toshihiro","family":"Miyamoto","sequence":"first","affiliation":[{"name":"Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sanford","sequence":"additional","affiliation":[{"name":"Leukemia\/Bone Marrow Transplant Program of BC, Division of Hematology, The University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciprian","family":"Tomuleasa","sequence":"additional","affiliation":[{"name":"Department of Hematology \u2013 Medfuture Research Center for Advanced Medicine, Ion Chiricuta Clinical Cancer Center, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Hua","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology-Oncology, Kaohsiung Medical University Hospital and Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Jos\u00e9 Enciso","family":"Olivera","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Cancerolog\u00eda, Bogot\u00e1, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoop Kumar","family":"Enjeti","sequence":"additional","affiliation":[{"name":"Calvary Mater Newcastle, University of Newcastle and New South Wales Health Pathology, Waratah, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Gimenez Conca","sequence":"additional","affiliation":[{"name":"Section of Hematology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2338-513X","authenticated-orcid":false,"given":"Teresa Bernal del","family":"Castillo","sequence":"additional","affiliation":[{"name":"Servicio de Hematolog\u00eda y Hemoterapia, University Hospital Central de Asturias, ISPA, IUOPA, Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Girshova","sequence":"additional","affiliation":[{"name":"Federal State Budgetary Institution \u2018Almazov National Medical Research Centre\u2019 of the Ministry of Health of the Russian Federation, St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Paola","family":"Martelli","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery \u2013 Section of Hematology and Clinical Immunology, Perugia University, \u2018Santa Maria della Misericordia\u2019 Hospital, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birol","family":"Guvenc","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, Cukurova University, Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Delgado","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghui","family":"Duan","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belen","family":"Garbayo Guijarro","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Llamas","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je-Hwan","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,2,11]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1406184"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm5030033"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00908-z"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13205"},{"key":"e_1_3_5_6_1","unstructured":"National Cancer Institute. Cancer stat facts: leukemia \u2013 acute myeloid leukemia [Internet]. [cited 2020 July 28]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html."},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010120"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.02.018"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.7525"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.05.024"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28129"},{"key":"e_1_3_5_12_1","first-page":"2020","article-title":"Clinical practice guidelines in oncology","volume":"3","author":"National Comprehensive Cancer Network","year":"2019","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Acute Myel Leuk. 2019;3:2020.","journal-title":"Acute Myel Leuk"},{"key":"e_1_3_5_13_1","unstructured":"Cancer.org. Typical treatment of acute myeloid leukemia (Except APL) [Internet]; 2020 [cited 2020 Nov 2]. Available from: https:\/\/www.cancer.org\/cancer\/acute-myeloid-leukemia\/treating\/typical-treatment-of-aml.html."},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07663.x"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03043.x"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.4245"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2714"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2019.01.008"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621664"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.0060"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.08.006"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2351-x"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-868752"},{"key":"e_1_3_5_25_1","unstructured":"DiNardo C Jonas B Pullarkat V et\u00a0al. A randomized double-blind placebo-controlled study of venetoclax with azacitidine vs azacitidine in treatment-na\u00efve patients with acute myeloid leukemia ineligible for intensive therapy-Viale-A. EHA Library. 06\/14\/20; 303390; LB2601."},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3803-6"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.9429"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30182-0"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.263"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-020-02856-3"},{"key":"e_1_3_5_31_1","unstructured":"Sorror M Storer B Elsawy M et\u00a0al. Relative benefit for intensive versus non-intensive induction therapy for patients with newly diagnosed acute myeloid leukemia (aml) using a composite age-comorbiditycytogenetic model. EHA Library. 06\/11\/16; 135337; LB580."},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16410"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.208637"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.188888"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002140"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0472-2"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25198"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2021.2002321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T17:23:36Z","timestamp":1700760216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2021.2002321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,11]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,3,21]]}},"alternative-id":["10.1080\/10428194.2021.2002321"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2021.2002321","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-06-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}